Time to cardiovascular benefits of empagliflozin: a post hoc observation from the EMPA‐REG OUTCOME trial

Time to cardiovascular benefits of empagliflozin: a post hoc observation from the EMPA‐REG OUTCOME trial

Abstract Aims In the EMPA‐REG OUTCOME trial, in patients with type 2 diabetes and established atherosclerotic cardiovascular (CV) disease, empagliflozin vs. placebo reduced the risk of hospitalization for heart failure (HHF) by 35%, CV death/HHF by 34%, and CV death by 38%, with an early separation...

Full description

Bibliographic Details
Main Authors: Subodh Verma, Lawrence A. Leiter, Bernard Zinman, Abhinav Sharma, Michaela Mattheus, David Fitchett, Jyothis George, Anne Pernille Ofstad, Mikhail N. Kosiborod, Christoph Wanner, Silvio E. Inzucchi
Format: Article
Language:English
Published: Wiley 2021-08-01
Series:ESC Heart Failure
Subjects:
Cardiovascular outcomes
Empagliflozin
Heart failure
Type 2 diabetes
Online Access:https://doi.org/10.1002/ehf2.13374

Internet

https://doi.org/10.1002/ehf2.13374

Similar Items